Israeli Biotech Company To Start Clinical Trials of CBD-Enhanced COVID-19 Treatment

Can a CBD-Steroid treatment help COVID-19 patients?

By
Thomas Edward

An Israel-based CBD company believes it may have a potential treatment for COVID-19.

Stero Biotechs announced this past weekend that it will start a clinical trial this month with the hope of mitigating the effects of those infected with the coronavirus. The study will begin immediately at Rabin Medical Center Golda HaSharon Campus in Petah Tikva, Israel. The company will test a steroid-CBD treatment on patients hospitalized due to the virus.

“Steroid treatment is usually the first or second line of treatment for hospitalized patients. CBD enhances the therapeutic effect of steroid treatment and treats the bio-mechanism affected by the virus,” Stero said in a press release. “The initial study will evaluate the tolerability, safety, and efficacy of the CBD treatment, for hospitalized patients with COVID-19 Infections.”

Stero Biotechs, which was founded about three years ago and has a headquarters in Israel, describes itself as “a clinical-stage company committed to the research and development of novel Cannabidiol (CBD) based treatment solutions that will potentially benefit millions of patients.”

David Bassa, the founder and chief executive officer of the company, said in a statement that the “CBD-based treatment can enhance the current treatment of those patients who are in life-threatening conditions.”

“Hospitalized COVID-19 patients are mostly being treated with steroids and our study is planned to demonstrate the benefit of a combined solution with Steroid treatments,” Bassa said. “We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.”

The initial trial will involve only 10 patients at Rabin Medical Center, but Stero said it ultimately “plans to scale up and expand to a phase 2a multi-center clinical trial, with an additional 40 hospitalized patients with COVID-19 Infections, under FDA clinical trial guidelines and regulations.”

The company said the initial “treatment cycle will be for a few weeks with a subsequent follow-up period of the same length.”

Thomas Edward

High Times Writer.

View Comments

By
Thomas Edward

Recent Posts

Research Shows Some Rolling Papers Have High Levels of Heavy Metals

A recent study shows that many rolling papers and cones have elevated levels of potentially…

19 hours ago

DMT Lab Discovered in Brentwood, California During Robbery Raid

Multiple suspects face numerous charges for alleged burglary, grand theft, manufacturing and possessing a controlled…

19 hours ago

MedMen Files for Bankruptcy

The once prominent cannabis company has now entered receivership, and its assets and operations will…

19 hours ago

New Mexico Governor Calls Homeland Security Secretary’s Response to Pot Seizures ‘Inappropriate’

Governor Michelle Lujan Grisham was “offended” by Homeland Security Secretary Alejandro Mayorkas’ response to her…

19 hours ago

States with Adult-Use Pot Saw Decrease in Alcohol Use, No Increase in Teen Substance Abuse

Adult-use cannabis laws and sales were not associated with an overall increase in teen substance…

19 hours ago

DEA Moves To Reclassify Cannabis Under Schedule III in Historic Move, Report Indicates

The DEA under the Biden administration finally proposed the process of moving cannabis to Schedule…

1 day ago